Matter of Ethics Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics:

• Company: Baxter International (as referenced in the context of the case study).
• Context: The case centers on the ethical dilemma of a pharmaceutical executive regarding the disclosure of adverse drug reactions.
• Key Figures: The case focuses on the potential $100M+ revenue impact of the drug in question versus the moral obligation to report clinical findings (Paragraphs 4-7).

Operational Facts:

• Process: Clinical trials are governed by FDA compliance standards. The delay of a product launch involves significant R&D sunk costs (Exhibit 2).
• Geography: Operations are global, with primary regulatory scrutiny occurring in the United States and European Union markets.

Stakeholder Positions:

• The Executive: Torn between fiduciary duty to shareholders and patient safety.
• Regulatory Bodies: Require full disclosure of all adverse clinical events.
• Shareholders: Expect quarterly growth targets to be met without interruption.

Information Gaps:

• Specific statistical significance of the adverse reactions in the clinical trial data is not fully disclosed in the case summary.
• The exact contractual penalties for delaying the product launch are not explicitly quantified.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question: How should the executive reconcile the immediate financial damage of a product delay with the long-term risk of regulatory litigation and reputational destruction?

Structural Analysis:

• Risk Management Framework: The cost of immediate transparency is a temporary stock price decline. The cost of non-disclosure is potential bankruptcy via class-action litigation and loss of operating licenses.

Strategic Options:

• Option 1: Immediate Disclosure. Halt the launch, report findings to the FDA. Trade-offs: Immediate revenue loss, potential CEO termination, but preserves the integrity of the firm.
• Option 2: Phased Disclosure. Launch with warning labels while conducting internal follow-up studies. Trade-offs: High litigation risk; seen as bad faith by regulators.
• Option 3: Full Suppression. Proceed with the launch as planned. Trade-offs: High short-term gain; catastrophic long-term survival risk.

Preliminary Recommendation: Option 1. The firm cannot survive a regulatory fraud charge. The financial hit is a manageable operational expense compared to the existential threat of a government-mandated shutdown.

3. Implementation Roadmap (Implementation Specialist)

Critical Path:

• Day 1-3: Assemble legal and clinical review board to finalize the disclosure document.
• Day 4: Direct communication with FDA leadership.
• Day 5: Preparation of investor relations statement to frame the delay as a proactive safety measure.

Key Constraints:

• Regulatory Timing: The FDA process cannot be accelerated; any sign of evasion will be punished.
• Internal Dissent: The sales team will resist the delay; they must be managed to prevent unauthorized leaks.

Risk-Adjusted Implementation:

• Assume a 6-month delay in product revenue. Re-allocate R&D budget to accelerate the next pipeline project to offset the gap. Build a contingency fund for potential stock volatility.

4. Executive Review and BLUF (Executive Critic)

BLUF: The executive must disclose the clinical findings immediately. This is not a matter of corporate strategy; it is a matter of corporate survival. Attempting to manage the disclosure to protect quarterly earnings will invite regulatory enforcement that will dismantle the firm. The board must be briefed today to ensure alignment on the narrative: proactive safety management is a feature of a high-quality pharmaceutical firm, not a failure. The cost of this transparency is a single quarter of missed targets. The cost of suppression is the company itself.

Dangerous Assumption: The analysis assumes the market will punish the company for the delay. In reality, the market punishes companies for lack of transparency. The market will react more favorably to a company that identifies a safety risk than to one that hides it.

Unaddressed Risks:

• Employee Retention: Top scientists may leave if they perceive a culture of safety suppression.
• Competitive Response: Rivals will use the delay to capture market share. This must be anticipated in the PR plan.

Unconsidered Alternative: The company could pivot to a partnership model for the drug, sharing the burden of the clinical delay with a larger partner who has the capital to weather the regulatory investigation.

Verdict: APPROVED FOR LEADERSHIP REVIEW.